Factors affecting the maintenance stable warfarin dosage in Hong Kong Chinese patients

Journal of Thrombosis and Thrombolysis

Volumn 20, Issue 1, 2005, Pages 33-38

  Lee, Vivian W Y ^a   You, Joyce H S ^a   Lee, Kenneth K C ^a   Chau, T S ^a   Waye, Mary M Y ^a   Cheng, Gregory ^a  

^a and Hong Kong Branch of CAS Center for Excellence in Animal Evolution and Genetics   (Hong Kong)

Author keywords

Anticoagulation; CYP2C9; Genetic polymorphism; Warfarin

Indexed keywords

ACETYLSALICYLIC ACID; ALLOPURINOL; AMIODARONE; CYTOCHROME P450 2C9; DEXTROPROPOXYPHENE; SIMVASTATIN; VITAMIN K GROUP; WARFARIN;

ADULT; AGE; AGED; ARTICLE; BLEEDING DISORDER; BLOOD SAMPLING; CHINESE; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DIETARY INTAKE; DOSE RESPONSE; DRINKING BEHAVIOR; DRUG POTENTIATION; FEMALE; GENETIC ANALYSIS; GENETIC POLYMORPHISM; GENETIC RISK; GENOTYPE; HEART ATRIUM FIBRILLATION; HEART FAILURE; HONG KONG; HUMAN; HYPERTENSION; INTERNATIONAL NORMALIZED RATIO; LINEAR REGRESSION ANALYSIS; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTIPLE REGRESSION; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SMOKING; STATISTICAL SIGNIFICANCE; VITAMIN SUPPLEMENTATION;

ADULT; ANTICOAGULANTS; ARYL HYDROCARBON HYDROXYLASES; ASIAN CONTINENTAL ANCESTRY GROUP; CARDIOVASCULAR DISEASES; DOSE-RESPONSE RELATIONSHIP, DRUG; EXONS; FEMALE; HONG KONG; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; WARFARIN;

EID: 24944555017     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11239-005-3121-8     Document Type: Article

References (24)

1. Takahashi H Echizen H. Pharmacogenetics of warfarin elimination and its clinical implications. Clinical Pharmacokinetics 2001; 40 8: 587-603. 11523725
2. Loebstein R Yonath H Peleg D, et al. Interindividual variability in sensitivity to warfarin - Nature or nurture? Clinical Pharmacology and Therapeutics 2001; 70: 159-164. 10.1067/mcp.2001.117444
3. Goldstein J.A. Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. British Journal of Clinical Pharmacology 2001; 52 4: 349-355. 10.1046/j.0306-5251.2001.01499.x
4. Lee C.R Goldstein J.A. Pieper J.A. Cytochrome P450 2C9 polymorphisms: A comprehensive review of the in-vitro and human data. Pharmacogenetics 2002; 12: 251-263. 10.1097/00008571-200204000-00010
5. Higashi M.K. Veenstra D.L. Kondo L.M. et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 2002; 287: 1690-1698. 10.1001/jama.287.13.1690
6. Leung A.Y.H. Chow H.C.H. Kwong Y.L. et al. Genetic polymorphism in exon 4 of cytochrome P450 CYP2C9 may be associated with warfarin sensitivity in Chinese patients. Blood 2001; 98: 2584-2587. 10.1182/blood.V98.8.2584
7. Couris RR Tataronis GR Booth SL et al. Development of a self-assessment instrument to determine daily intake and variability of dietary vitamin K. Journal of the American College of Nutrition 2000; 19 6: 801-807. 11194535
8. Chang J.G. No exon 3 polymorphism of cytochrome P450 CYP2C9 in Taiwanese. Blood 2003; 101: 5086-5087. 10.1182/blood-2003-02-0467
9. Yu H.C.M. Chan T.Y.K. Critchley J.A.J. et al. Factors determining the maintenance dose of warfarin in Chinese patients. QJM 1996; 89 2: 127-135 8729554
10. Absher R K Moore M E Parker M H et al. Patient-specific factors predictive of warfarin dosage requirements. Annals of Pharmacotherapy 2002; 36 10: 1512-1517. 10.1345/aph.1C025
11. Blann A Hewitt J Siddiqui F et al. Racial background is a determinant of average warfarin dose required to maintain the INR between 2.0 and 3.0. British Journal of Haematology 1999; 107 1: 207-209. 10.1046/ j.1365-2141.1999.01672.x
12. Roberts G.W. Helboe T Nielsen C.B.M. et al. Assessment of an age-adjusted warfarin initiation protocol. Annals of Pharmacotherapy 2003; 37 6: 799-803. 10.1345/aph.1A372
13. Khan T Kamali F Daly A et al. Warfarin sensitivity: Be aware of genetic influence. Age & Ageing 2003; 32 2 226-227.
14. Kamali F Khan T.I. King B.P. et al. Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin. Clinical Pharmacology & Therapeutics 2004; 75 3: 204-212.
15. Roberts G.W. Gallus A.S. Druskeit T et al. Comparison of an age adjusted warfarin loading protocol with empirical dosing and Fennerty's protocol. Australian and New Zealand Journal of Medicine 1999; 29 5: 731-736. 10630656
16. Kamali F Edwards C Butler T.J. et al. The influence of (R)- and (S)-Warfarin, vitamin K and vitamin K epoxide upon warfarin anticoagulation. Thrombosis & Haemostasis 2000; 84 1: 39-42.
17. Ammash N Warnes C.A. Cerebrovascular events in adult patients with cyanotic congenital heart disease. Journal of the American College of Cardiology 1996; 28 3: 768-772. 10.1016/0735-1097(96)00196-9
18. Ha C.E. Petersen C.E. Park D.S. et al. Investigations of the effects of ethanol on warfarin binding to human serum albumin. Journal of Biomedical Science 2000; 7 2: 114-121. 10.1159/000025436
19. James A.H. Britt R.P. Raskino C.L. et al. Factors affecting the maintenance dose of warfarin. Journal of Clinical Pathology 1993; 46 4: 382-383.
20. Hylek E.M. Regan S. Go A.S. et al. Clinical predictors of prolonged delay in return of the international normalized ratio to within the therapeutic range after excessive anticoagulation with warfarin. Annals of Internal Medicine 2001; 135 6: 393-400. 11560452
21. Wong R.S.M. Cheng G. Chan T.Y.K. Use of herbal medicines by patients receiving warfarin. Drug Safety 2003; 26 8: 585-588. 12825970
22. Couris R.R. Tataronis G.R. Booth S.L. et al. Development of a self-assessment instrument to determine daily intake and variability of dietary vitamin K. Journal of the American College of Nutrition 2000; 19 6: 801-807. 11194535
23. Miller L.G. Herbal medicinals: Selected clinical considerations focusing on known or potential drug-herb interactions. Archives of Internal Medicine 1998; 158 20: 2200-2211. 10.1001/archinte.158.20.2200
24. Khan T Wynne H Wood P et al. Dietary vitamin K influences intra-individual variability in anticoagulant response to warfarin. British Journal of Haematology 2004; 124 3: 348-354. 10.1046/ j.1365-2141.2003.04787.x